Department of Anesthesia, Montreal General Hospital, McGill University Health Centre, Montreal, Quebec, Canada.
Currently a medical student at Montreal General Hospital, McGill University Health Centre, Montreal, Quebec, Canada.
JAMA Surg. 2020 Mar 1;155(3):233-242. doi: 10.1001/jamasurg.2019.5474.
Research supports use of prehabilitation to optimize physical status before and after colorectal cancer resection, but its effect on postoperative complications remains unclear. Frail patients are a target for prehabilitation interventions owing to increased risk for poor postoperative outcomes.
To assess the extent to which a prehabilitation program affects 30-day postoperative complications in frail patients undergoing colorectal cancer resection compared with postoperative rehabilitation.
DESIGN, SETTING, AND PARTICIPANTS: This single-blind, parallel-arm, superiority randomized clinical trial recruited patients undergoing colorectal cancer resection from September 7, 2015, through June 19, 2019. Patients were followed up for 4 weeks before surgery and 4 weeks after surgery at 2 university-affiliated tertiary hospitals. A total of 418 patients 65 years or older were assessed for eligibility. Of these, 298 patients were excluded (not frail [n = 290], unable to exercise [n = 3], and planned neoadjuvant treatment [n = 5]), and 120 frail patients (Fried Frailty Index,≥2) were randomized. Ten patients were excluded after randomization because they refused surgery (n = 3), died before surgery (n = 3), had no cancer (n = 1), had surgery without bowel resection (n = 1), or were switched to palliative care (n = 2). Hence, 110 patients were included in the intention-to-treat analysis (55 in the prehabilitation [Prehab] and 55 in the rehabilitation [Rehab] groups). Data were analyzed from July 25 through August 21, 2019.
Multimodal program involving exercise, nutritional, and psychological interventions initiated before (Prehab group) or after (Rehab group) surgery. All patients were treated within a standardized enhanced recovery pathway.
The primary outcome included the Comprehensive Complications Index measured at 30 days after surgery. Secondary outcomes were 30-day overall and severe complications, primary and total length of hospital stay, 30-day emergency department visits and hospital readmissions, recovery of walking capacity, and patient-reported outcome measures.
Of 110 patients randomized, mean (SD) age was 78 (7) years; 52 (47.3%) were men and 58 (52.7%) were women; 31 (28.2%) had rectal cancer; and 87 (79.1%) underwent minimally invasive surgery. There was no between-group difference in the primary outcome measure, 30-day Comprehensive Complications Index (adjusted mean difference, -3.2; 95% CI, -11.8 to 5.3; P = .45). Secondary outcome measures were also not different between groups.
In frail patients undergoing colorectal cancer resection (predominantly minimally invasive) within an enhanced recovery pathway, a multimodal prehabilitation program did not affect postoperative outcomes. Alternative strategies should be considered to optimize treatment of frail patients preoperatively.
ClinicalTrials.gov identifier: NCT02502760.
研究支持在结直肠癌切除术前和术后使用预康复来优化身体状况,但它对术后并发症的影响仍不清楚。虚弱的患者是预康复干预的目标人群,因为他们术后结局较差的风险增加。
评估与术后康复相比,预康复计划对接受结直肠癌切除术的虚弱患者 30 天术后并发症的影响程度。
设计、设置和参与者:这是一项单盲、平行臂、优效性随机临床试验,于 2015 年 9 月 7 日至 2019 年 6 月 19 日在 2 家大学附属的三级医院招募接受结直肠癌切除术的患者。所有患者在手术前 4 周和手术后 4 周(共 4 周)接受随访。共有 418 名 65 岁或以上的患者符合条件。其中,298 名患者因不符合条件(非虚弱[290 名]、无法锻炼[3 名]和计划新辅助治疗[5 名])而被排除,120 名虚弱患者(Fried 虚弱指数≥2)被随机分组。10 名患者在随机分组后被排除,因为他们拒绝手术(3 名)、术前死亡(3 名)、无癌症(1 名)、无肠切除术(1 名)或转为姑息治疗(2 名)。因此,共有 110 名患者被纳入意向治疗分析(预康复组 55 名,康复组 55 名)。数据于 2019 年 7 月 25 日至 8 月 21 日进行分析。
包括术前(预康复组)或术后(康复组)开始的多模式运动、营养和心理干预。所有患者均在标准化的强化康复途径内接受治疗。
主要结局指标为术后 30 天的综合并发症指数。次要结局指标包括 30 天的总并发症和严重并发症、主要和总住院时间、30 天内急诊就诊和再次住院、行走能力恢复情况以及患者报告的结局指标。
110 名随机患者的平均(SD)年龄为 78(7)岁;52 名(47.3%)为男性,58 名(52.7%)为女性;31 名(28.2%)患有直肠癌;87 名(79.1%)接受了微创手术。主要结局指标(调整后的平均差异,-3.2;95%CI,-11.8 至 5.3;P=0.45)在两组之间无差异。次要结局指标也无差异。
在接受结直肠癌切除术(主要为微创手术)且接受强化康复途径治疗的虚弱患者中,多模式预康复方案并未影响术后结局。应考虑替代策略来优化虚弱患者的术前治疗。
ClinicalTrials.gov 标识符:NCT02502760。